News Conference News ACC 2021 Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC Michael O'Riordan May 17, 2021
News Conference News ACC 2021 Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO Michael O'Riordan May 16, 2021
News Conference News ACC 2021 Low 1-Year Stroke Risk After Commercial Watchman Use Todd Neale May 15, 2021
News Conference News ACC 2021 PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI L.A. McKeown May 15, 2021
News Conference News ACC 2021 ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI Yael L. Maxwell May 15, 2021
News Conference News ACC 2021 Occluding the LAA During Surgery Lowers Stroke Risk: LAAOS III Todd Neale May 15, 2021
News Conference News ACC 2020 LAAO Registry: Safety of Watchman Looks Good in First Years of Rollout Todd Neale April 06, 2020
News Conference News ACC 2020 Aspirin Okay for Up to 30 Days in A-fib Patients After ACS or PCI: AUGUSTUS Todd Neale April 03, 2020
News Conference News ACC 2020 Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT Todd Neale April 02, 2020
News Conference News ACC 2020 A-fib Patients Undergoing TAVR Do Better With OAC Alone: POPular TAVI Todd Neale March 29, 2020
News Conference News ACC 2020 Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds Todd Neale March 25, 2020
Presentation ACC 2019 Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial Presenter: Renato Lopes March 18, 2019
News Conference News ACC 2019 New Primary Prevention Guidelines Axe Aspirin, Pushing Routine Check-ins, Social Clues Instead Michael O'Riordan March 17, 2019
News Conference News ACC 2019 Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery Michael O'Riordan March 17, 2019
News Conference News ACC 2019 AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI Caitlin E. Cox March 17, 2019
News Conference News ACC 2019 Apple Watch May Detect A-fib in the General Population, but at What Cost? Yael L. Maxwell March 16, 2019
News Opinion Editor's Corner ACC 2019 Live From New Orleans: Opening Day at ACC 2019 Shelley Wood March 16, 2019
News Conference News ACC 2019 ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend Shelley Wood March 11, 2019
News Conference News ACC 2018 Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4 Todd Neale March 13, 2018
Presentation ACC 2018 Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticoagulants Presenter: Steve Deitelzweig March 12, 2018